# Acoziborole

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/acoziborole
Canonical HTML page: https://getyourbrief.com/entity/acoziborole

## Timeline

- **2026**: Rollout Milestone — Acoziborole enters the final stages of regulatory rollout for endemic regions.
- **2026**: Acoziborole Rollout — The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies.
- **2022**: Trial Results — Phase 2/3 clinical trial results for Acoziborole show high efficacy.
- **2018**: Fexinidazole Approval — First all-oral 10-day treatment for sleeping sickness is approved.
- **2018**: Fexinidazole Approval — The first all-oral treatment is approved, requiring 10 days of pills taken with food.
- **2009**: Research Begins — DNDi starts screening compounds for a single-dose HAT treatment.
- **2009**: NECT Launch — Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
- **1949**: Melarsoprol Introduced — Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.

## Recent coverage (2 stories, network-wide)

### Single-Dose Breakthrough: Acoziborole Signals End for Sleeping Sickness
2026-03-16 21:50:22 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
Full story: https://getbiobrief.com/story/acoziborole-sleeping-sickness-breakthrough-2026

### Single-Dose Breakthrough: Acoziborole Signals End of Sleeping Sickness
2026-03-16 21:44:53 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
Full story: https://gethealthbrief.com/story/acoziborole-sleeping-sickness-elimination-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.